Roche Elecsys® Vitamin D Total assay provides accurate results and fast turnaround times – labs in Coventry, London and Kingston share their experiences

   

Omega Diagnostics Group PLC has announced the imminent launch of VISITECT^® CD4, a ground-breaking point-of-care (POC) disposable test for the detection of CD4 T-cell levels, aimed at reaching HIV-positive patients across the globe. VISITECT^® CD4, developed by the Burnet Institute in Melbourne, Australia, is an affordable POC test that enables CD4 T-cell levels to be determined, quickly and conveniently, even in remote rural areas in resource-poor countries. This easy-to-use, semi-quantitative lateral flow test uses a finger-prick blood sample and produces a straightforward visual result in just 40 minutes, enabling patients to receive life-saving antiretroviral treatment before leaving the clinic. Minimal training is required and no additional instruments are necessary, eliminating the need for sophisticated equipment, expensive reagents and highly trained personnel. 

Oxfordshire UK [Marlborough, MA]; June 18th, 2012 – Oxford Immunotec, a medical diagnostic company developing tests in the fields of infectious and immunological disease, announced today that it has raised a total of $28m in a new equity financing. The round was led by new investors Imperial Innovations and Invesco Perpetual and supported by existing shareholders, including Clarus, New Leaf, DFJ Esprit, Wellington, SPARK Ventures, the Dow Chemical Company, NTEC, Kaiser Permanente Ventures and the University of Oxford. Oxford Immunotec has now completed five institutional funding rounds totaling approximately $110 million since its establishment in 2002.

  

Geneva, 14.06.2012 -- The executive board of UNITAID today approved funding of US$ 30 million to scale up access to a new diagnostic test for tuberculosis, Xpert MTB/RIF, and reduce the cost of its use.

The new liquid stable homocysteine kit from Randox provides a convenient and accurate method for the determination of homocysteine in human serum and plasma. Homocysteine is a potential indicator of a number of disease markers and should therefore be an integral part of a laboratory’s testing menu. 

The jury of the European Inventor Award has nominated the team of Klaus Hallermayer from Roche Penzberg, jointly with Prof. Hugo Katus from the University of Heidelberg, for their invention concerning the "specific antibodies to troponin T, their production and their use in a reagent for the determination of heart muscle necrosis".